-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $67

Benzinga·04/16/2026 16:40:27
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $50 to $67.